Oral antidiabetics in 2003;Les antidiabétiques oraux en 2003

Revue Medicale de Bruxelles

Volumn 24, Issue 4, 2003, Pages

  Ducobu, J ^a  

^a Centre Hospitalier Universitaire de Tivoli   (Belgium)

Author keywords

Biguanides; Glinides; Glitazones; Sulfonylureas; Type 2 diabetes

Indexed keywords

ACARBOSE; AMARYLLE; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; ENZYME INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; GLYCOSIDASE INHIBITOR; INSULIN; LIPASE INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG CHOICE; EDEMA; ENZYME INHIBITION; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; INTESTINE ABSORPTION; LACTIC ACIDOSIS; LIVER DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RISK FACTOR; SIDE EFFECT; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 0141995814     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607
2. Panzram G: Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 123-31
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998; 352: 837-53
4. American Diabetes Association: Clinical practice recommendations 2002. Diabetes Care 2002 (Suppl 1): 533-41
5. Groop L: Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-54
6. Nathan DM: Initial Management of glycemia in type 2 diabetes. N Engl J Med 2002; 347: 1342-9
7. Fuhlendorff J, Rorsman P, Kofod H et al: Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-51
8. Cusi K, DeFronzo RA: Metformin: a review of its metabolic effects. Diabetes Rev 1998; 6: 89-131
9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65
10. Olefsky JM: Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106: 467-72
11. Yang WS, Jeng CY, Wu TJ et al: Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-80
12. Ducobu J, Sternon J: Les glitazones. Rev Med Brux 2000; 21: 441-6
13. Coniff R, Krol A: Acarbose: A review of US clinical experience. Clint Ther 1997; 19: 16-26
14. Muls E, Kolanowski J, Scheen A, Van Gaal I: The effects of orlistat on weight and on sezum lipids in obese patients with hypercholesterolemia: a randomised, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25: 1713-21
15. Cusi K, Cunningham GR, Comstock JP: Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 1995; 18: 843-51
16. th ed. New York, Mc Graw-Hill, 2002: 515-22
17. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12
18. Ilkowa H, Glaser B, Tunckale A, Bagriacik N, Cerasi E: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353-6
19. American diabetes Association and National Institute of Diabetes and Digestive and Kidney Diseases: The prevention or delay of type 2 diabetes. Diabetes Care 2002; 25: 742-9